IMNM logo

IMNM
Immunome Inc

2,226
Mkt Cap
$2.45B
Volume
513.00
52W High
$27.65
52W Low
$7.96
PE Ratio
-9.10
IMNM Fundamentals
Price
$21.66
Prev Close
$22.96
Open
$22.98
50D MA
$22.01
Beta
1.56
Avg. Volume
976,741.54
EPS (Annual)
-$2.43
P/B
4.16
Rev/Employee
$39,214.69
$1,226.67
Loading...
Loading...
News
all
press releases
What Offers Immunome (IMNM) a Compelling Investment Opportunity?
What Offers Immunome (IMNM) a Compelling Investment Opportunity...
News Placeholder
More News
News Placeholder
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2026, and provided a business update. This quarter reflects the progress we are making in...
News Placeholder
Techne (TECH) Misses Q3 Earnings and Revenue Estimates
Techne (TECH) delivered earnings and revenue surprises of -2.75% and -2.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Exelixis (EXEL) Tops Q1 Earnings Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +15.55% and -0.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the Company) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the...
News Placeholder
Truist Financial Upgrades Immunome (NASDAQ:IMNM) to Strong-Buy
Truist Financial upgraded shares of Immunome to a "strong-buy" rating in a report on Monday...
News Placeholder
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -12.39% and -82.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Immunome (IMNM) to Release Earnings on Monday
Immunome (NASDAQ:IMNM) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-immunome-inc-stock...
News Placeholder
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application...
News Placeholder
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
Immunome, Inc. (Immunome) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available